FourThought Financial Partners LLC Buys 50,120 Shares of Novo Nordisk A/S $NVO

FourThought Financial Partners LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 641.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 57,934 shares of the company’s stock after acquiring an additional 50,120 shares during the quarter. FourThought Financial Partners LLC’s holdings in Novo Nordisk A/S were worth $3,999,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Laurel Wealth Advisors LLC lifted its position in Novo Nordisk A/S by 6,802.0% during the second quarter. Laurel Wealth Advisors LLC now owns 224,661 shares of the company’s stock valued at $15,506,000 after purchasing an additional 221,406 shares during the period. Aviso Financial Inc. lifted its holdings in shares of Novo Nordisk A/S by 1.9% during the 2nd quarter. Aviso Financial Inc. now owns 37,822 shares of the company’s stock valued at $2,610,000 after buying an additional 702 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in shares of Novo Nordisk A/S by 86.2% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 138,214 shares of the company’s stock worth $9,540,000 after buying an additional 63,980 shares during the last quarter. Jaffetilchin Investment Partners LLC purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter worth $409,000. Finally, Insigneo Advisory Services LLC grew its holdings in shares of Novo Nordisk A/S by 164.2% in the second quarter. Insigneo Advisory Services LLC now owns 24,099 shares of the company’s stock worth $1,663,000 after acquiring an additional 14,977 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on NVO shares. BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research report on Wednesday, August 13th. HSBC cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, November 17th. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Stock Performance

NVO opened at $44.99 on Tuesday. The firm has a market cap of $200.88 billion, a P/E ratio of 12.36, a PEG ratio of 2.33 and a beta of 0.65. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $112.52. The company has a 50 day simple moving average of $53.71 and a two-hundred day simple moving average of $60.14. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.74 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.